Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Completes Cash Tender Offer for ViaCell

NEW YORK (GenomeWeb News) - PerkinElmer said today it has completed its successful tender offer to acquire ViaCell by buying more than 90 percent of the company's outstanding common stock.
 
PerkinElmer said it purchased approximately 37.9 million ViaCell shares through the tender offer, which expired Thursday night. PerkinElmer paid $7.25 a share for a total of more than $274 million.  
 
The company said it plans to buy ViaCell’s remaining shares through a short-form merger under Delaware law for the same price, at which time ViaCell will become a wholly owned PerkinElmer subsidiary.
 
When the deal is closed, PerkinElmer plans to sell ViaCell's therapeutics business
 

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.